Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - publicum.umed.lodz.pl
Purpose: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
J Byrd, P Hillmen, P Ghia, A Kater… - JOURNAL OF …, 2021 - avesis.istanbul.edu.tr
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - europepmc.org
Purpose Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than
ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - JOURNAL OF …, 2021 - iris.unisr.it
Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib,
which we hypothesized would improve continuous therapy tolerability. We conducted an …
which we hypothesized would improve continuous therapy tolerability. We conducted an …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - escholarship.org
PurposeAmong Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than
ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
[引用][C] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan… - 2021 - oparu.uni-ulm.de
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> Among Bruton's tyrosine kinase
inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would …
inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would …
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - devnauka.pib-nio.pl
PURPOSEAmong Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
[引用][C] Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
JC Byrd, P Hillmen, P Ghia, AP Kater… - Journal of Clinical …, 2021 - ruj.uj.edu.pl
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : results of the
first randomized phase III trial W dniach od 2 kwietnia do 5 kwietnia 2024 r. prowadzone będą …
first randomized phase III trial W dniach od 2 kwietnia do 5 kwietnia 2024 r. prowadzone będą …